9.25
+0.01 (+0.11%)
9.26
+0.01 (+0.11%)
ChartMill assigns a Buy % Consensus number of 60% to KIN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.69. This target is 4.76% above the current price.
KIN was analyzed by 5 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about KIN.
In the last month the buy percentage fell by 8 points. So the trust of analysts is decreasing.
Only 5 analysts analyzed KIN. So this is just the average opinion of a couple of analysts.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-06-17 | Lake Street | Downgrade | Buy -> Hold |
| 2021-06-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-06-16 | Aegis Capital | Downgrade | Buy -> Hold |
Kindred Biosciences / KIN FAQ
What do analysts expect the price target to be for Kindred Biosciences (KIN)?
5 analysts have analysed KIN and the average price target is 9.69 null. This implies a price increase of 4.76% is expected in the next year compared to the current price of 9.25.
What is the consensus rating for KIN stock?
The consensus rating for Kindred Biosciences (KIN) is 60 / 100 . This indicates that analysts generally have a neutral outlook on the stock.